Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 11—November 2004

Histopathologic Improvement with Lymphedema Management, Léogâne, Haiti

Susan F. Wilson*, Jeannette Guarner*, Alix L. Valme†, Jacky Louis-Charles†, Tara L. Jones*, and David G. Addiss*Comments to Author 
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hôpital Ste. Croix, Léogâne, Haiti

Main Article

Table 4

Demographic, physical, and treatment-related characteristics of 27 patients with initial and follow-up skin biopsy specimens, by degree of histologic improvement (involving >4 vs. <4 histologic characteristics), Léogâne, Haiti

Factors examined Improvement in >4 
histologic characteristics Improvement in <4 
histologic characteristics
Number of patients 11 16
Female (%) 9 (82) 11 (69)
Median age, y (range) 39 (20–61) 32 (16–61)
Stage of lymphedema (%)
  Stage 1 2 (18) 0 (0)
  Stage 2 5 (45) 13 (81)
  Stage 3 4 (36) 3 (19)
Median no. of days in lymphedema management before 
1st biopsy (range) 21 (0–432) 19.5 (0–468)
Median no. of days between biopsies (range) 359 (317–503) 366 (317–656)
Median annual incidence of ADLA between biopsies (range) 0 (0–2) 0 (0–3)
Median duration of lymphedema, y (range) 11.5 (4–27) 7 (0–25)

Main Article

Page created: April 22, 2011
Page updated: April 22, 2011
Page reviewed: April 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.